(於開曼群島註冊成立的有限公司) （股份代號：1277） 關連交易 二零二零年貸款協議第三份補充協議 茲提述本公司日期為二零二零年六月二十二日、二零二二年十二月二十三日及二零 二四年二月九日的公告，其中披露，本公司之間接全資附屬公司力量（秦皇島）（作 為貸方）與貴州力量（作為借方）於二零二零年六月二十二日訂立二零二零年貸款協 議，據此，貸方同意向借方提供一筆本金額為人民幣57百萬元（相當於約63百萬港 元）之貸款，自計息日起為期兩年。於二零二二年十二月二十三日，力量（秦皇島）與 貴州力量訂立二零二零年貸款協議補充協議，據此，訂約方同意將貸款的還款日期 延長至二零二三年十二月三十一日。於二零二四年二月九日，力量（秦皇島）與貴州 力量訂立二零二零年貸款協議第二份補充協議，據此，訂約方同意將貸款的還款日 期進一步延長至二零二五年十二月三十一日。除上文所述者外，二零二零年貸款協 議及補充協議的其他條款及條件將繼續具有十足效力及作用。 1 於二零二五年十二月二十二日，力量（秦皇島）與貴州力量訂立二零二零年貸款協 議第三份補充協議，據此，訂約方同意將貸款的還款日期進一步延長至二零二七年 十二月三十一日，利率上調至全國銀行 ...

Core Insights - The Dutch government needs to invest at least $177 billion in high-tech industries over the next decade to ensure continued economic prosperity [1] - The report highlights challenges such as slow digital development, difficulties in clean energy transition, severe aging population, housing shortages, and pressure on public services [1] - The investment focus should be on four key areas: digitalization and artificial intelligence, life sciences and biotechnology, security technology, and energy and climate technology, which are expected to see significant international demand growth [1] Summary by Sections Investment Needs - The report suggests that by 2035, the government should maintain investments in high-tech industries between $177 billion and $220 billion to sustain economic growth rates of 1.5% to 2.0% [1] Recommendations for Reform - Accelerate approval processes and simplify regulatory execution for key projects to enhance national competitiveness [2] - Strengthen talent supply through structured retraining and skill enhancement programs, attracting more international talent [2] - Improve energy conditions by adjusting energy sources and tax incentives in the short term, while developing a more robust energy mix for long-term stability [2] - Enhance infrastructure by focusing on key projects like Rotterdam and Schiphol airports and the Leiden bioscience park [2] Institutional Proposals - Establish a cross-departmental economic agency directly overseen by the Prime Minister to coordinate policy implementation [2] - Propose the creation of a national investment bank focused on public-private investments in technology and infrastructure, leveraging €10 billion to €20 billion in capital to attract over €100 billion in investments [2] - Recommend the establishment of a national innovation agency with a budget of €2 billion to support innovative ecosystems and strategic breakthrough projects [2]

Group 1 - The coal stocks in Hong Kong are experiencing a decline, with notable drops in companies such as Qinfa down over 6%, Yancoal Australia down nearly 4%, and China Coal Energy down 3.5% [1] - The price of thermal coal has decreased, with the Qinhuangdao port price for Q5500 thermal coal at 791 RMB per ton as of December 6, reflecting a week-on-week drop of 27 RMB per ton [1] - According to a report from Cinda Securities, weak coal demand is expected to continue, and supply constraints are unlikely to provide significant support. The current phase is seen as the early stage of a new upward cycle for the coal economy, suggesting that it may be a good time to accumulate coal sector stocks [1] Group 2 - The daily coal consumption at power plants remains below expectations due to higher-than-normal temperatures across the country, putting pressure on port and production prices [1] - The forecast for the next 1-2 weeks indicates that temperatures will continue to be higher than usual, limiting demand release and suggesting that coal prices are likely to continue their weak adjustment trend [1]

Group 1 - Coal stocks in Hong Kong have experienced a decline, with Qinfa falling over 6% [1] - Other companies such as Power Development, China Coal Energy, and China Shenhua also saw declines [1]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Group 1 - The company, 力量山西, has agreed to acquire 100% equity of 太原实地 from 遵义实地 for a total price of RMB 384,000,000, with a remaining payable amount of RMB 130,266,000 after offsetting the amounts already paid for the property by 2025 [1] - A share transfer agreement has been established between 力量山西 and 遵义实地 regarding the acquisition of 太原实地 [1] - 力量秦皇岛 has entered into a debt repayment agreement with 广东实地 and 北京实地, which includes the acquisition of properties located at 东直门, with a total cost of RMB 86,330,000 for two properties [1]

Group 1 - The company has entered into a sixth supplemental agreement regarding the property transfer, terminating the rights and responsibilities under the 2022 property purchase agreement for properties not yet registered for transfer [1] - The company will acquire 100% equity of Taiyuan Real Estate from Zunyi Real Estate for a total consideration of RMB 384 million, with a remaining balance of RMB 130 million payable after offsetting amounts already paid [1] - The company has agreed to purchase two properties located in Dongzhimen, Beijing, for a total of RMB 86.33 million, with net payable amounts after tax and debt offsets totaling RMB 56.89 million [2] Group 2 - As of the announcement date, the company has paid RMB 803 million for the acquisition of further adjusted target properties for 2024, but the registration process is not yet complete [3] - The company is actively seeking suitable assets to replace the delayed registration of the 2024 properties and has secured the acquisition of 100% equity of Taiyuan Real Estate as a safeguard [3] - The Dongzhimen properties are considered high-quality assets with strong capital appreciation potential, aligning with the company's strategic goals [3]

Group 1 - The company has entered into a sixth supplemental agreement regarding the property transfer, terminating the rights and responsibilities under the 2022 property purchase agreement for properties not yet registered for transfer [1] - The company will acquire 100% equity of Taiyuan Real Estate from Zunyi Real Estate for a total consideration of RMB 384 million, with a balance of RMB 130 million payable after offsetting amounts already paid for properties [1] - The company has agreed to purchase two properties located in Dongzhimen, Beijing, for a total of RMB 86.33 million, with net payable amount after tax and debt offsets being RMB 56.89 million [2] Group 2 - As of the announcement date, the company has paid RMB 803 million for the acquisition of further adjusted target properties for 2024, but the registration process for these properties is still incomplete [3] - The company is actively seeking suitable assets to replace the delayed registration of the 2024 properties and has secured the acquisition of 100% equity of Taiyuan Real Estate [3] - The Dongzhimen properties are considered high-quality assets with strong capital appreciation potential, aligning with the company's strategic goals [3]

Group 1 - The company announced a sixth supplemental agreement regarding the sale of properties, terminating the rights and responsibilities related to unsold properties as of the effective date of the agreement [1] - The company agreed to acquire 100% equity of Taiyuan Shidi from Zunyi Shidi for a total consideration of RMB 384 million, with a remaining balance of approximately RMB 130 million after offsetting amounts already paid [1] - A share transfer agreement was established between the company and Zunyi Shidi for the acquisition of Taiyuan Shidi [1] Group 2 - The company entered into a debt repayment agreement involving the acquisition of Dongzhimen properties, with a total consideration of RMB 86.33 million for two properties [2] - The agreement includes provisions for tax liabilities and debts to be paid by the company on behalf of Beijing Shidi, totaling RMB 1.105 million and RMB 4.89 million respectively [2] - After deducting the aforementioned amounts, the net payable amount for the Dongzhimen properties is RMB 56.89 million, which will be offset against 2024 payables [2]

茲提述本公司日期為二零二二年五月二日、二零二二年七月十二日、二零二三年 十二月一日、二零二三年十二月十二日、二零二四年二月七日、二零二四年六月 三日、二零二四年六月六日、二零二四年九月六日、二零二四年十一月四日、二零 二四年十一月十二日及二零二五年一月十三日之公告（「該等公告」）及本公司日期 為二零二二年九月三十日、二零二四年二月二十一日、二零二四年十一月二十五 日及二零二四年十二月十九日之通函（「該等通函」）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (於開曼群島註冊成立的有限公司) （股份代號：1277） Kinetic Development Group Limited 力量發展集團有限公司 須予披露及關連交易 收購太原實地 及 關連交易 收購東直門物業 獨立董事委員會及獨立股東的獨立財務顧問 緒言 太原實地收購事項的背景 1 於二零二二年四月二十九日，原賣方與本公司間接全資附屬公司力量秦皇島簽訂 二零二二年物業購買協議，據此，原賣方同 ...